Another strategy uses a mixture of antibodies that target EGFR (epidermal growth factor receptor), which are expressed in a subset of metaplastic breast cancer [67], to promote the lysosomal degradation of EGFR [68]. The gene discussed is EGFR; the disease is breast carcinoma.